By virtue of their powerful position in the pharmaceuticals and diagnostics sectors, Taj Pharmaceuticals is predestined to develop tailor-made solutions for diagnostic and therapeutic problems. Against the background of the first disease management projects conducted between 1996 and 1998 – in particular in the field of viral disease (HIV and hepatitis C) – innovative programmes for different clinical pictures and fields have been developed to face up to the challenges of modern medicine today and in the future.

Taj Pharmaceutical's approach of integrated solutions aims at developing such combinations of diagnostic and therapeutic products in close cooperation with the divisions concerned and bringing them to our customers.

The incorporation of the new technological possibilities offered by genome research can lead in the medium term to treatment that is customized to the individual needs of each patient. Integrated solutions such as this will not only benefit the patient, the will also simplify the situation for the various healthcare funders.

In order to develop timely diagnostic and therapeutic solutions of this nature, the possibilities of future programmes are evaluated while research is still going on during the preclinical phase of new therapies.

The aim of concerted activities is to broaden the range of services provided by Taj Pharmaceuticals by developing and marketing combined diagnostic and therapeutic concepts, thus generating values for our clients and Taj Pharmaceuticals alike. The foundations for the realisation of this objective rest on three pillars:

• Early and improved recognition of patients who may benefit from Taj Pharmaceutical's substances;

• Improved and more accurate identification of patients for the therapies offered;

• Optimisation and control of therapy by monitoring treatment results.